Summary Information:
Rubius Therapeutics Inc. Common Stock
NASDAQ:RUBY
email
admin@troach.net 		Our Main Pages
Stocks.TRoach.Net
TRoach.Org
TRoach.Net
NOTE: This page is for evaluation of a JFF Project.
This page is NOT updated on a regular basis.
Information on this page should NOT be used for investment purposes.
Rubius Therapeutics Inc. Common Stock
Exchange: NASDAQ
Symbol: RUBY
SEC CIK: 0001709401
Phone: 617-679-9600
399 BINNEY STREET, SUITE 300
CAMBRIDGE MA 02139

CEO: Pablo Cagnoni
Price Quote by TradingView
Price when page updated: 0.254 Date: 2023-02-01
Company Website:
www.rubiustx.com

_Description: Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas.

IPO YEAR:
2018
 Sector:
Health Care
 Industry:
Biotechnology: Biological Products (No Diagnostic Substances)
ADRTSO:

MarketCap:
22954369.00
 Beta:
1.071097203951177
52 Week High:
38.71
 52 Week Low:
6.75
 52 Week Change:
0.3668407310704962
Short Interest:

Short Date:

Shares Outstanding:
89865777
Dividend Rate:
0
 Dividend Yield:
2.43%
ExDividend Date:

Latest EPS:

Latest EPS Date:
25 Oct 2022
Float:
0
return on Equity:
6.20%
 Consensus EPS:

Number Of Estimates:
EPS Surprise Dollar:

Eps Surprise Percent:

EBITDA:
$9.133B
ttmEPS:
0
 Revenue:
$65.287B
 Gross Profit:
Cash:

Debt:

Institution Percent:
81.40%
Revenue Percent:

Revenue Per Employee:

Insider Percent:
0.10%
Return on Assets:
2.80%
 Return on Capital:

Profit Margin:
6.80%
Price to Sales:
2.06
 Price To Book:
1.86
 Short Ratio:
1.36
PE Ratio:
0
 Employees:
204
 1Y Guesstimate
5.250:13.0:2


__The following are links to various summary and news pages for
__Rubius Therapeutics Inc. Common Stock [ RUBY ].

__Note: Some Links might not have information for the company.


finance.Yahoo.com money.CNN.com NASDAQ research
WalletInvestor.com WSJ.com MarketBeat.com
finviz.com WallMine.com TheGlobeandMail.com
stock1010.com
NASDAQ - General Info SEC Insider Report Ownership Summary
Dividend History insiderbuyingselling.com
Facebook search Twitter search LinkedIn search
PRnewsWire.Com Google Forecast
tdameritrade.com BarChart.com
SeekingAlpha.com Markets.FT.com stocktwits.com
FinTel.io Ldmicro.com bloomberg.com
MarketWatch.com Reuters.com businessinsider.com
fool.com barrons.com zacks.com
GuruFocus.com Investing.com tipranks.com
thestreet.com nytimes.com earningswhispers.com
marketchameleon.com sunshineavenue.com stockinvest.us
stockanalysis.com stockconsultant.com ycharts.com
financialcontent.com docoh.com foxbusiness.com
cnbc.com investorsobserver.com tradingview.com
investopedia.com tmxmoney.com invest.cnyes.com
ask.com bing.com brave.com
duckduckgo.com ecosia.org excite.com
exalead.com gibiru.com hotbot.com
www.info.com infospace.com lycos.com
lukol.com metacrawler.com mojeek.com
becovi.com searx.thegpm.org search.com
swisscows.com webcrawler.com yahoo.com
yandex.com yep.com you.com




INDEX



Page design by: TRoach
Page Last Updated: 2023-02-01